Yüklüyor......
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for th...
Kaydedildi:
| Yayımlandı: | J Hepatocell Carcinoma |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5118026/ https://ncbi.nlm.nih.gov/pubmed/27896243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S106072 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|